Phlebotomy or bloodletting: From tradition to evidence-based medicine

Transfusion

Volumn 52, Issue 3, 2012, Pages 460-462

  Jhang, Jeffrey S ^a   Schwartz, Joseph ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITRIC ACID; FERRITIN; IRON; TRANSFERRIN;

CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; CYTAPHERESIS; DISEASE SEVERITY; DIZZINESS; EDITORIAL; ERYTHROCYTAPHERESIS; EVIDENCE BASED MEDICINE; FERRITIN BLOOD LEVEL; GENE MUTATION; GENETIC DISORDER; HEMOCHROMATOSIS; HISTORY OF MEDICINE; HUMAN; INTERMETHOD COMPARISON; IRON OVERLOAD; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PHLEBOTOMY; POLYCYTHEMIA VERA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME;

BLOOD COMPONENT REMOVAL; ERYTHROCYTES; FEMALE; HEMOCHROMATOSIS; HUMANS; MALE; PHLEBOTOMY;

EID: 84858225229     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03548.x     Document Type: Editorial

References (27)

1. Greenstone G,. The history of bloodletting. BCMJ 2010; 52: 12-4.
2. Adams PC, Barton JC,. How I treat hemochromatosis. Blood 2010; 116: 317-25.
3. Ganz T,. Hepcidin and iron regulation, 10 years later. Blood 2011; 117: 4425-33.
4. Conte D, Brunelli L, Bozzani A, Tidone L, Quatrini M, Bianchi PA,. Erythrocytapheresis in idiopathic haemochromatosis. Br Med J (Clin Res Ed) 1983; 286: 939. (Pubitemid 13152764)
5. Conte D, Mandelli C, Cesana M, Ferrini R, Marconi M, Bianchi A,. Effectiveness of erythrocytapheresis in idiopathic hemochromatosis. Report of 14 cases. Int J Artif Organs 1989; 12: 59-62. (Pubitemid 19036800)
6. Fernandez-Mosteirin N, Salvador-Osuna C, Garcia-Erce JA, Orna E, Perez-Lungmus G, Giralt M,. [Comparison between phlebotomy and erythrocytapheresis of iron overload in patients with HFE gene mutations]. Med Clin (Barc) 2006; 127: 409-12. (Pubitemid 44682648)
7. Kellner H, Zoller WG,. Repeated isovolemic large-volume erythrocytapheresis in the treatment of idiopathic hemochromatosis. Z Gastroenterol 1992; 30: 779-83. (Pubitemid 23008795)
8. Kohan A, Niborski R, Daruich J, Rey J, Bastos F, Amerise G, Herrera R, Garcia M, Olivera W, Santarelli MT, Avalos JS, Findor J,. Erythrocytapheresis with recombinant human erythropoietin in hereditary hemochromatosis therapy: a new alternative. Vox Sang 2000; 79: 40-5.
9. Mariani R, Pelucchi S, Perseghin P, Corengia C, Piperno A,. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. Haematologica 2005; 90: 717-8. (Pubitemid 40780906)
10. Muncunill J, Vaquer P, Galmes A, Obrador A, Parera M, Bargay J, Besalduch J,. In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy. J Clin Apher 2002; 17: 88-92. (Pubitemid 34809557)
11. Rombout-Sestrienkova E, van Noord PA, van Deursen CT, Sybesma BJ, Nillesen-Meertens AE, Koek GH,. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis-a pilot study. Transfus Apher Sci 2007; 36: 261-7. (Pubitemid 47089103)
12. Zoller WG, Kellner H, Spengel FA,. Erythrocytapheresis. A method for rapid extracorporeal elimination of erythrocytes. Results in 65 patients. Klin Wochenschr 1988; 66: 404-9.
13. Rombout-Sestrienkova E, Nieman FHM, Essers BAB, van Noord PAH, Janssen MCH, van Deursen CThBM, Bos LP, Rombout F, van den Braak R, de Leeuw PW, Koek GH,. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion 2012; 52: 470-7.
14. Pietrangelo A,. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 2010; 139: 393-408, e1-2.
15. Pietrangelo A,. The ferroportin disease. Blood Cells Mol Dis 2004; 32: 131-8. (Pubitemid 38147710)
16. Politou M, Kalotychou V, Pissia M, Rombos Y, Sakellaropoulos N, Papanikolaou G,. The impact of the mutations of the HFE gene and of the SLC11A3 gene on iron overload in Greek thalassemia intermedia and beta(s)/beta(thal) anemia patients. Haematologica 2004; 89: 490-2. (Pubitemid 38798554)
17. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, Loukopoulos D, Camaschella C,. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33: 21-2. (Pubitemid 36068676)
18. Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M, Majorano N, Totaro A, Gasparini P,. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14-5. (Pubitemid 30257027)
19. Hanson EH, Imperatore G, Burke W,. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001; 154: 193-206. (Pubitemid 32701154)
20. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR,. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2006; 145: 209-23. (Pubitemid 46780566)
21. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ,. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34: 275-8. (Pubitemid 27208030)
22. Davis WD Jr, Arrowsmith WR,. The effect of repeated bleeding in Hemochromatosis. J Lab Clin Med 1950; 36: 814-5.
23. Falize L, Guillygomarc'h A, Perrin M, Laine F, Guyader D, Brissot P, Turlin B, Deugnier Y,. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006; 44: 472-7. (Pubitemid 44214887)
24. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G,. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107-19. (Pubitemid 26113751)
25. McDonnell SM, Preston BL, Jewell SA, Barton JC, Edwards CQ, Adams PC, Yip R,. A survey of 2851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999; 106: 619-24. (Pubitemid 29279297)
26. Dabestani A, Child JS, Henze E, Perloff JK, Schon H, Figueroa WG, Schelbert HR, Thessomboon S,. Primary hemochromatosis: anatomic and physiologic characteristics of the cardiac ventricles and their response to phlebotomy. Am J Cardiol 1984; 54: 153-9. (Pubitemid 14085367)
27. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH,. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25: 83-177.